Development of a novel humanized liver model with alcoholic liver fibrosis

Active Grant Awarded

Award ID
R21AA032616
Recipient
Awarding agency
Obligated
$426,563

Award facts

Assistance listing
93.273 Alcohol Research Programs
Completion date 10% complete
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of the University of Pennsylvania, doing business as University of Pennsylvania, $426,563 on September 9, 2026. The grant, R21AA032616, is funded under Alcohol Research Programs (CFDA 93.273).

The award funds development of a novel humanized liver model of alcohol-associated liver disease fibrosis. The recipient has developed and recently published a mouse model with a human chimeric liver, composed of human hepatocytes and most non-parenchymal cells, including human immune, endothelial, and stellate cells. Preliminary data show these humanized livers respond to ten days of ethanol treatment with early-stage human alcohol-associated liver disease features, including moderate to severe steatosis, Mallory-Denk hyaline inclusions, marked human monocyte/T cell liver infiltration, cholestasis, and peripheral lymphopenia. The recipient aims to use these livers to develop animal models that exhibit advanced fibrosis in the context of alcoholic liver disease.

The period of performance runs from September 9, 2026 to August 31, 2028, and the work is performed in Philadelphia, Pennsylvania. The program supports research to build a knowledge base for improved treatment and prevention of alcoholism and alcohol-related problems.

Description

Abstract
Liver fibrosis and associated liver dysfunction contribute to an estimated 2 million deaths ANNUALLY1,2. Alcohol associated liver disease (AALD) is a major driver of liver fibrosis. Despite significant efforts, there are no effective therapies for fibrosis, particularly concerning AALD, which lacks a relevant model that fully recapitulates the complex interactions between human liver cell populations. Rodents are more resistant to alcoholic liver damage than humans, and transcriptomic cross-species analysis of liver fibrosis reveals that only 40% of gene expression changes are shared between humans and RODENTS3. This underscores the urgent need for humanized models of fibrosis. For the first time, we have developed and recently published a mouse model with a human chimeric liver, composed of human hepatocytes and the majority of non-parenchymal cells (NPCS), including human immune, endothelial, and stellate cells. These humanized livers reproduce human liver architecture, zonation, and perform vital human-specific metabolic and homeostatic processes. Additionally, they model human pathologies, including steatohepatitis and fibrosis. We have demonstrated through preliminary data that these humanized livers respond to ten days ethanol treatment with key pathological features of early-stage human AALD, including moderate to severe steatosis and mallory-denk hyaline inclusions in human hepatocytes, marked human monocyte/T cells liver infiltration, cholestasis, and peripheral LYMPHOPENIA4-features that have not appeared in rodent models exposed to short and long alcohol treatments. This is the first time such functional and pathological humanization has been achieved, offering a unique model to investigate human pathobiology. Using these humanized livers, we aim to develop animal models that exhibit advanced stages of fibrosis in the context of alcoholic liver disease within a human liver microenvironment. In aim 1, we will increase the humanization of cholangiocytes, which have been shown to expand in patients with moderate to severe fibrosis and to correlate with disease severity. We will examine their effect in early-stage fibrosis in two weeks of alcohol diet. In the AIM2, we will treat humanized liver mice for extended periods of time with ethanol diet to induce moderate to severe fibrosis and we will compare the transcriptome to human AALD with similar histological stage. This model of liver fibrosis in humanized livers will provide a unique tool for future R01 studies, enabling the in vivo investigation of molecules found deregulated in fibrotic human livers. This approach will yield more clinically relevant data, ultimately facilitating a smoother translation from bench to bedside.

Quick answers

Who received award R21AA032616?

R21AA032616 was awarded to The Trustees Of The University Of Pennsylvania by National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health) on September 9, 2026.

How much is award R21AA032616 worth?

$426,563 has been obligated on R21AA032616.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award